Press Release

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: co.secretary@biocon.com www.biocon.com BIO/SECL/TG/2026-27/80 November 04, 2026 To, To, The Manager The Manager BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate Communication Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai – 400 001 Mumbai – 400 051 Scrip Code - 532523 Scrip Symbol – BIOCON Subject: Press Release on financial results for the quarter and half-year ended September 30, 2026 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled “Biocon Q2FY27 Total Income at Rs 4,423 Cr; EBITDA at Rs 865 Cr; Net Profit at Rs 41 Cr; Biopharma Revenue Up 5%” pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter and half-year ended September 30, 2026. The above information will also be available on the website of the Company at www.biocon.com. Kindly take the above information on record and acknowledge. Thanking You, Yours faithfully, For Biocon Limited Rajesh U. Shanoy Company Secretary and Compliance officer ICSI Membership Number: A16328 Enclosed: Press Release and Fact Sheet PRESS RELEASE Biocon Q2FY27 Total Income at Rs 4,423 Cr; EBITDA at Rs 865 Cr; Net Profit at Rs 41 Cr; Biopharma Revenue Up 5% Bengaluru, Karnataka, India: November 4, 2026: Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal second quarter ended September 30, 2026. FINANCIAL PERFORMANCE • Consolidated operating revenue increased 2% YoY to Rs 4,389 crore. • Biopharma revenue increased 5% YoY to Rs 3,583 crore. o Biosimilars revenue increased 3% YoY to Rs 2,809 crore. o Generics revenue increased 10% YoY Rs 774 crore. • Services revenue increased 13% QoQ to Rs 833 crore. Note: Revenue contribution as a % of Revenue from Operations • Consolidated EBITDA stood at Rs 865 crore. • Interest cost continued to trend lower during the quarter, declining 12% YoY to Rs 240 crore, following the actions taken to strengthen the balance sheet. • Net Profit before exceptional items was Rs 44 crore. • Secured a landmark 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at ~USD 400 million. LEADERSHIP COMMENTS “Biocon continued to achieve industry firsts in biosimilars, with our Pertuzumab becoming the first monoclonal antibody biosimilar recommended under the EMA’s new tailored clinical development pathway. This represents an important milestone for biosimilar innovation and patient access. The operationalization of our second Insulin Glargine fill-finish line in Malaysia, with commercial supplies already underway, further reaffirms our global manufacturing excellence. Together with our continued investments in technology and innovation, these milestones reflect the progress of our strategic transformation and reinforce our confidence in Biocon’s long-term growth trajectory.” – Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited “This quarter we continued to make significant progress on our strategic priorities, laying the foundation for a stronger second half of FY27. Our global settlement with Genentech for Pebrilzo® (biosimilar Pertuzumab) secured the earliest licensed launch dates across Europe, UK, the U.S. and emerging markets providing greater visibility to a significant future growth driver. We also secured a landmark 10- year Pertuzumab PDP partnership in Brazil valued at ~USD 400 million, underscoring our ability to win and execute large-scale biologics deals. Together with the upcoming European launch of Pertuzumab, expanded insulin manufacturing capacity in Malaysia to support growing U.S. demand, and the strong early momentum of Yesafili™ and Yesintek® in the U.S., we are well positioned for growth in the second half of FY27.” – Shreehas Tambe, CEO & Managing Director, Biocon Limited “Syngene delivered 13% sequential revenue growth in Q2, supported by positive traction in our CDMO business, with operating EBITDA margin improving by 6 percentage points. Year-on-year revenue declined 9%, while operating EBITDA margin stood at 18%, in line with expectations, primarily reflecting lower Zoetis revenues and forex hedge losses. A key milestone in the quarter was the signing of our first manufacturing agreement for the Bayview biologics facility in the U.S. Our focus remains on improving our integrated drug discovery offering, commercial execution, asset utilization and cost competitiveness to drive sustainable growth.” – Siddharth Mittal, CEO & Managing Director, Syngene International Limited FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q2FY27 & H1FY27 In Rs Crore YoY (%) YoY (%) Particulars Q2FY27 Q2FY26 H1FY27 H1FY26 (Quarter) (Half year) INCOME Biosimilars 2,809 2,721 3% 5,664 5,179 9% Generics 774 701 10% 1,536 1,332 15% Biopharma (Biosimilars + 3,583 3,422 5% 7,200 6,511 11% Generics) Services 833 911 (9%) 1,569 1,785 (12%) Inter-segment (27) (37) (44) (58) Revenue from 4,389 4,296 2% 8,725 8,237 6% operations# Other income 34 93 (63%) 89 173 (48%) Total Income 4,423 4,389 1% 8,814 8,410 5% Net R&D Expenses 237 251 (6%) 477 455 5% EBITDA 865 928 (7%) 1,767 1,774 0% EBITDA Margins 20% 22% 20% 22% PBT (before Exceptional 62 183 (66%) 203 297 (32%) items) PBT (after Exceptional 55 171 (68%) 182 268 (32%) items^) Net Profit (before 44 92 (52%) 189 133 42% Exceptional Items^^) Net Profit (Reported) 41 85 (52%) 182 116 57% Figures above are rounded off to the nearest Crore; % based on absolute numbers. Notes to financials above: #Revenue from operations includes licensing income ^Exceptional items during Q2FY27 and Q2FY26 amount to Rs (7) crore and Rs (12) crore, respectively ^^Net of tax, minority interest and exceptional items during Q2FY27 and Q2FY26 amounted to Rs. (3) crore and Rs. (7) crore respectively, resulting in a Net Profit of Rs 41 crore and Rs 85 crore, respectively BUSINESS PERFORMANCE - Biopharma • Secured earliest licensed launch dates for Pebrilzo® (biosimilar Pertuzumab) across the EU, UK, U.S. and other Rest of the World countries through a global patent settlement with Genentech. North America • Continued to gain market share for Yesintek® (biosimilar Ustekinumab) in the U.S. • Successfully commercialized Yesafili™ (aflibercept-jbvf) in the U.S., as an interchangeable biosimilar Aflibercept. • Secured over USD 100 million in new contracts and major payor wins for commercialized products across the U.S. and witnessed strong demand for Insulin Glargine. • Secured regulatory approvals for the Yesintek® autoinjector in the U.S. and Canada. Europe • Received a positive CHMP opinion for Biocon’s biosimilar Pertuzumab, the first monoclonal antibody biosimilar recommended under the EMA's new tailored clinical development approach. • Strengthened Biocon’s position in key therapeutic areas through the commercialization of biosimilar Ustekinumab autoinjector (immunology), biosimilar Denosumab (bone health) and biosimilar Aflibercept (ophthalmology) across several European markets. • Received MHRA (UK) approval, in addition to EMA approval, for the second drug product fill-finish line for Insulin Glargine at insulin manufacturing facility in Malaysia. Emerging Markets • Secured a landmark 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at ~USD 400 million, supporting long-term adoption across the country’s public oncology network. • Executed 13 successful product launches across multiple therapeutic areas in APAC, LATAM and AFMET-CIS regions. Secured 13 regulatory approvals across key markets. BUSINESS PERFORMANCE - Services • Syngene strengthened its integrated drug discovery offering by bringing its Chemistry, Biology and Biotherapeutics capabilities under [Showing first 8,000 characters — download PDF for full document]